Pharmacoeconomic review report : Nitisinone (MDK-Nitisinone) (MendeliKABS inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Enzyme inhibitors.

Physical Description:

1 online resource (22 pages) : illustrations

Other Title:

Pharmacoeconomic review report Nitisinone

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

Nitisinone (MDK-Nitisinone) is an inhibitor of the tyrosine catabolic pathway and is indicated for patients with hereditary tyrosinemia type 1 (HT-1), in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules. The submitted price of nitisinone is based on dose: (2 mg $14.78), 5 mg ( 4.18), 10 mg (

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other Health Technology Assessment Reviews of the Drug

Appendix 5. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.

Includes bibliograhical references.